Table 4 Subgroup analyses of change in serum ALT in patients with chronic hepatitis C after treatment with UDCA
Dose (mg/ day)No. of patientsChange (%),median (range)p Value
vs 150 mgvs 600 mg
Gender
    Male15097−14.9 (−80.7 to +375.9)
600117−33.1 (−88.3 to +93.1)<0.001
900123−36.4 (−79.1 to +1696.9)<0.0010.430
    Female15098−18.0 (−79.0 to +175)
60081−25.0 (−74.7 to +95.2)0.058
90070−35.8 (−81.4 to +315.3)0.0020.076
Body weight (kg)
    <60150115−14.9 (−80.7 to +375.9)
60082−28.6 (−74.7 to +95.2)0.002
90091−35.2 (−81.4 to +315.3)0.0010.356
    ⩾6015080−16.7 (−73.4 to +166.1)
600116−30.3 (−88.3 to +93.1)0.003
900102−36.6 (−77.1 to +1696.9)<0.0010.096
GGT (IU/l)
    ⩽3915045−14.5 (−73.4 to +71.4)
60039−32.7 (−62.9 to +93.1)0.049
90045−26.6 (−81.4 to +1696.9)0.1120.616
    40–7915079−15.2 (−69.1 to +175)
60090−30.3 (−74.7 to +95.2)0.001
90070−36.3 (−77.7 to +200)<0.0010.633
    ⩾8015071−18.2 (−80.7 to +375.9)
60069−28.6 (−88.3 to +53.8)0.057
90078−41.2 (−79.1 to +119.3)<0.0010.004
  • The p values refer to Wilcoxon signed-ranks tests.